NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
Clinical Trials
35 trialsNCT01938833 2025-05-16
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Thomas Jefferson University
Phase 1/2 Terminated
NCT01834235 2025-05-07
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Phase 1/2 Terminated
NCT00583349 2025-02-17
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Columbia University
Phase 1/2 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03189914 2023-12-06
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Processa Pharmaceuticals
Phase 1/2 Completed
NCT01325441 2023-11-15
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02178436 2023-11-07
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02382406 2023-05-23
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT02194829 2023-04-25
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT03138889 2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02210559 2023-03-02
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
Phase 1/2 Completed
NCT01647828 2023-02-15
ALPINE
Mereo BioPharma
Phase 1/2 Completed
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02379247 2022-06-07
BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT02810418 2022-03-15
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02562898 2021-05-06
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT00442260 2021-01-22
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
West Virginia University
Phase 1/2 Completed
NCT00851877 2020-08-21
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01431794 2020-01-22
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT00398086 2019-11-22
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Celgene
Phase 1/2 Completed
NCT01893801 2019-05-29
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Pancreatic Cancer Research Team
Phase 1/2 Completed
NCT02075021 2018-10-15
rev/abraxane
NYU Langone Health
Phase 1/2 Terminated
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT00570674 2017-11-13
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00748553 2017-07-26
VA
University of Utah
Phase 1/2 Completed
NCT00544648 2014-06-09
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated